Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv) by Batra, J. K. et al.
Vol. 11, No. 4MOLECULAR AND CELLULAR BIOLOGY, Apr. 1991, p. 2200-2205
0270-7306/91/042200-06$02.00/0
Copyright C) 1991, American Society for Microbiology
Single-Chain Immunotoxins Directed at the Human Transferrin
Receptor Containing Pseudomonas Exotoxin A or
Diphtheria Toxin: Anti-TFR(Fv)-PE40 and
DT388-Anti-TFR(Fv)
JANENDRA K. BATRA, DAVID J. FITZGERALD, VIJAY K. CHAUDHARY, AND IRA PASTAN*
Laboratory of Molecular Biology, Division of Cancer Biology, Diagnosis and Centers,
National Cancer Institute, Bethesda, Maryland 20892
Received 5 November 1990/Accepted 18 January 1991
Two single-chain immunotoxins directed at the human transferrin receptor have been constructed by using
polymerase chain reaction-based methods. Anti-TFR(Fv)-PE40 is encoded by a gene fusion between the DNA
sequence encoding the antigen-binding portion (Fv) of a monoclonal antibody directed at the human transferrin
receptor and that encoding a 40,000-molecular-weight fragment of Pseudomonas exotoxin (PE40). The other
fusion protein, DT388-anti-TFR(Fv), is encoded by a gene fusion between the DNA encoding a truncated form
of diphtheria toxin and that encoding the antigen-binding portion of antibody to human transferrin receptor.
These gene fusions were expressed in Escherichia coli, and fusion proteins were purified by conventional
chromatography techniques to near homogeneity. In anti-TFR(Fv)-PE40, the antigen-binding portion is placed
at the amino terminus of the toxin, while in DT388-anti-TFR(Fv), it is at the carboxyl end of the toxin. Both
these single-chain immunotoxins kill cells bearing the human transferrin receptors. However, anti-TFR(Fv)-
PE40 was usually more active than DT388-anti-TFR(Fv), and in some cases it was several-hundred-fold more
active. Anti-TFR(Fv)-PE40 was also more active on cell lines than a conjugate made by chemically coupling the
native antibody to PE40, and in some cases it was more than 100-fold more active.
Immunotoxins made by chemically coupling tumor-spe-
cific monoclonal antibodies to bacterial or plant toxins,
including Pseudomonas exotoxin (PE) and diphtheria toxin
(DT) have been shown to possess in vitro and in vivo
antitumor activity (10, 19, 24). Both PE and DT kill cells by
ADP-ribosylating elongation factor 2, thereby inhibiting pro-
tein synthesis. X-ray crystallographic and mutational analy-
ses show the PE molecule to be made up of three distinct
domains, namely, an amino-terminal cell-binding domain, a
middle translocation domain, and a carboxyl-terminal ac-
tivity domain (1, 12). DT, which is divided into two chains,
A and B, linked by a disulfide bridge, is arranged func-
tionally in the orientation opposite to that of PE. Chain B of
DT, which is at the carboxyl end, is responsible for receptor
binding, and chain A, at the amino end, contains the enzy-
matic activity (22, 23). Apparently the last 150 amino acids
of DT are responsible for its cell-binding activity (21-
23).
We have constructed immunotoxins by attaching antibod-
ies either to native PE that has an Mr of 66 kDa or to
truncated forms of PE that lack its cell-binding domain and
have an Mr of about 40 kDa (referred to as PE40). Immuno-
toxins made with PE40 or LysPE40, a PE40 derivative with
an extra lysine residue at its amino terminus that facilitates
coupling to antibodies, have greater specificity for target
cells because PE cannot bind to its cellular receptor (3, 13,
20). One such immunotoxin, anti-TFR-LysPE40, was shown
to be highly cytotoxic to cells expressing the human trans-
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ferrin receptor. When given intraperitoneally to mice, it
caused regression of A431 tumors growing as subcutaneous
xenografts (3). Immunoconjugates with low nonspecific tox-
icity have also been made by using modified DT with
mutations in its cell-binding domain (17, 25).
Immunotoxins constructed by chemical cross-linking are
heterogeneous and are difficult to produce in large amounts
because the antibody and toxin must be made and purified
separately and then conjugated in a reaction that often has a
low yield. To address this problem, we have made two
recombinant single-chain immunotoxins directed at the inter-
leukin-2 receptor. The two are termed anti-Tac(Fv)-PE40 and
DT388-anti-Tac(Fv). The Fv fragment is the smallest binding
unit of an antibody which consists of a light- and a heavy-
chain variable domain. Both single-chain immunotoxins con-
sist of the variable domains of a monoclonal antibody directed
at the interleukin-2 receptor arranged in a single-chain form
and linked to the amino terminus of PE40 (2, 9) or to the
carboxyl end of a truncated form of DT (7). Single-chain
immunotoxins are constructed by starting with hybridoma
RNA, using polymerase chain reaction (PCR) to amplify the
DNA encoding the variable heavy and variable light chains of
the antibodies, and inserting this DNA into an expression
vector containing PE40 sequences (4). We used this rapid
cloning technique and now report the construction of two
single-chain immunotoxins, anti-TFR(Fv)-PE40 and DT388-
anti-TFR(Fv). In anti-TFR(Fv)-PE40, the single-chain anti-
TFR(Fv), containing the variable heavy chain of a monoclo-
nal antibody (HB21) to the human transferrin receptor (anti-
TFR) (11) linked through a peptide linker to its variable light
chain, is fused to the amino terminus of PE40. In DT388-anti-
TFR(Fv), the single-chain anti-TFR(Fv) is linked to the
carboxyl end of the truncated DT. Both of these single-chain
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FIG. 1. (A) Scheme for construction of plasmid pJB anti-TFR(Fv)-1108 encoding anti-TFR(Fv)-PE40. N, NdeI; B, BamHI; H, Hind III;
X, XbaI; S, Sall; E, EcoRI. Fifteen amino acids of the linker are shown in single-letter code. (B) Structure of oligonucleotides used for PCR.
(C) Expression plasmid pJBDT1-anti-TFR(Fv).
immunotoxins were expressed in Escherichia coli and puri-
fied to near homogeneity. Anti-TFR(Fv)-PE40 and DT388-
anti-TFR(Fv) were very cytotoxic to cell lines bearing hu-
man transferrin receptors, but large and unexpected
differences in the activities of these molecules on target cells
were detected.
MATERIALS AND METHODS
Plasmid constructions. The scheme for construction of
expression plasmid pJB-anti-TFR(Fv)-1108 encoding anti-
TFR(Fv)-PE40 is shown in Fig. 1A. Isolation of RNA,
cDNA first-strand synthesis, and PCR conditions have been
described previously (4). Primers used to amplify the vari-
able domains are shown in Fig. 1B. The purified PCR
products were digested with NdeI and BamHI for the
fragment encoding VH and part of the linker at its 3' end or
with BamHI and HindIlI for VL and the rest of the linker at
its 5' end. Expression vector pVC38H was digested with
NdeI and HindIII and dephosphorylated with calf intestinal
phosphatase. The DNA fragments were purified on Sea-
Plaque agarose gel. A three-fragment ligation was set up with
3.6-kb dephosphorylated vector and VH and VL fragments.
The recombinants were screened with XbaI, Sall, HindIII,
A
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and BamHI. Several positive clones were checked for pro-
tein expression in BL21 (XDE3).
Figure 1C shows the plasmid used for the expression of
DT388-anti-TFR(Fv). To construct this plasmid, PCR with
pJB-anti-TFR(Fv)-1108 as template was used to amplify
DNA for anti-TFR(Fv) such that it had NdeI at the 5' end
and EcoRI at the 3' end. The PCR-amplified fragment was
restricted with NdeI and EcoRI and ligated to pVC-DT-IL2
(6, 7) digested with NdeI and EcoRI. The recombinants were
screened with HindIII, BamHI, and NdeI. pVC-DT1-IL2
contains the first 388 codons of DT with the initiator methi-
onine fused to cDNA encoding human interleukin-2 (6).
Protein expression and purification. BL21 (XDE3) cells
were transformed with the plasmids pJB anti-TFR(Fv)-1108
or pJB DT388-anti-TFR(Fv). The cells were grown in super-
broth containing 100 ,ug of ampicillin per ml at 37°C. At an
A650 of 0.8, cells were induced with 1 mM isopropyl-p-D-
thiogalactopyranoside (IPTG). Cells were harvested 90 min
later, and the location of the fusion protein was determined
as described elsewhere (5). The fusion protein was isolated
from the inclusion bodies by denaturation in 7 M guanidine
HCl and renaturation by rapid dilution in phosphate-buffered
saline. After dialysis, the renatured protein was applied to an
8-ml Q-Sepharose column. Proteins were batch eluted from
the column with 0.1, 0.35, and 1 M NaCl. The pool contain-
ing the desired fusion protein (0.35 M salt eluate) was diluted
and loaded onto a Mono Q 10/10 fast protein liquid chroma-
tography column. The fusion protein was eluted by a linear
gradient of 0 to 0.5 M NaCl in 0.02 M Tris (pH 7.4). Further
purification was achieved by gel filtration chromatography
on a TSK 250 column.
Cytotoxicity assay. Cytotoxic activities of anti-TFR(Fv)-
PE40, anti-TFR-LysPE40, and DT388-anti-TFR(Fv) were
determined by assaying the inhibition of protein synthesis as
measured by [3H]leucine incorporation into total cell protein
(9). The results are expressed as percentage of control, to
which no toxin was added. For competition experiments, 20
jig of antibody was added per well prior to the addition of the
toxin (9).
Binding studies. 125I-labeled HB21 (20 ,uCi/,ug) was added
as a tracer at 1.5 ng per assay with various concentrations of
competitor and 4 x 105 HUT102 cells or 5 x 105 A431 cells
in 0.2 ml of binding buffer (RPMI 1640 with 10% fetal bovine
serum, 100 ,ug of human immunoglobulin per ml, and 0.1%
sodium azide) and incubated at room temperature with
shaking for 2 h. At the end of the incubation, cells were
washed three times with the binding buffer and counted in a
gamma counter (9).
Other methods. Anti-TFR-LysPE40 was constructed as
described elsewhere (3). Protein was assayed by Bradford's
method with Bio-Rad protein assay reagent (3a). Sodium
dodecyl sulfate-polyacrylamide gel electrophoresis was done
by the method of Laemmli (14).
RESULTS
Plasmid construction, protein expression, and purification.
The structure of a plasmid encoding anti-TFR(Fv)-PE40 is
shown in Fig. 1A. The assembled gene is under the control of
a bacteriophage T7 promoter. The plasmid expresses the
first -110 amino acids of anti-TFR heavy chain, a 15-amino-
acid linker containing (Gly4Ser)3, the first -100 amino acids
of anti-TFR light chain, and amino acids 253 to 613 of PE.
The expression plasmid pJB-DT388-anti-TFR(Fv) shown in
Fig. 1C encodes the first 388 amino acids of DT fused to the
variable heavy domain of anti-TFR antibody, which is
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FIG. 2. Sodium dodecyl sulfate-polyacrylamide gel electropho-
resis of anti-TFR(Fv)-PE40 (A) and DT388-anti-TFR(Fv) (B) at
different steps of purification. Lane 1, Inclusion bodies; lane 2,
Mono Q pool; lane 3, TSK gel filtration pool. Gel was stained with
Coomassie blue. Numbers at left are molecular sizes in kilodaltons.
connected to its variable light chain through the (Gly4Ser)3
linker. Anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv) were
expressed in E. coli (BL21 XDE3), and after induction with
IPTG, the fusion proteins were contained primarily in the
inclusion bodies. The fusion protein from the inclusion
bodies was denatured in 7 M guanidine HCl and renatured by
rapidly dilution in phosphate-buffered saline. Purification
was performed by chromatography on a Q-Sepharose anion-
exchange column and then on a Mono Q fast protein liquid
chromatography column. The pool containing the active
protein was finally purified by gel filtration on a TSK 250
column. The purity of anti-TFR(Fv)-PE40 and DT388-anti-
TFR(Fv) at each purification step is shown in Fig. 2A and B,
respectively. The protein after gel filtration chromatography
appeared to be >90% pure and was used for all subsequent
studies.
Cytotoxicity and specificity of anti-TFR(Fv)-PE40. As
shown in Fig. 3, anti-TFR(Fv)-PE40 was extremely active
and inhibited the protein synthesis of A431 cells in a dose-
dependent manner with a 50% inhibitory dosage (ID50) of
0.02 nglml, which is equivalent to 0.2 pM (Table 1). The
cytotoxic effect was blocked by competition with excess
-
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FIG. 3. Cytotoxicity of anti-TFR(Fv)-PE40 on A431 cells. Cells
were incubated with the toxin for 16 to 20 h and pulsed with
[3H]leucine, and radioactivity was measured in the trichloroacetic
acid-precipitable protein. Results are shown as percentage of con-
trol, to which no toxin was added. Symbols: 0, anti-TFR(Fv)-PE40
alone; 0, anti-TFR(Fv)-PE40 plus 20 ,ug of OVB3; *, anti-TFR(Fv)-
PE40 plus 20 ,ug of HB21. HB21 is a monoclonal antibody to the
human transferrin receptor produced by the hybridoma used as the
source of RNA for cloning the variable domains.
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TABLE 1. Activity of anti-TFR(Fv)-PE40 on various
human cell lines
ID50 (pM)
Cell Origin Anti- Anti- Relativeline TFR(Fv)- TFR- activity'
PE40 LysPE40
A431 Epidermoid 0.18 20 111
carcinoma
KB Epidermoid 0.10 75 750
carcinoma
MCF7 Breast carcinoma 0.14 13.5 96
OVCAR3 Ovarian carcinoma 8.0 1,000 125
HUT102 Adult T-cell leukemia 37.0 50 1.3
HT29 Colon carcinoma 45.0 160 3
PC3 Prostate carcinoma 58.5 280 5
LNCAP Prostate carcinoma 2.6 10 4
DU145 Prostate carcinoma 92.0 400 4
L929 Fibroblast (mouse) >30,000 >10,000
Swiss 3T3 Fibroblast (mouse) >30,000 >10,000
a Ratio of activity of anti-TFR(Fv)-PE40 to activity of anti-TFR-LysPE40
on the same cell line.
anti-TFR, whereas OVB3, a control antibody, did not block
the cytotoxicity, demonstrating the specificity of anti-
TFR(Fv)-PE40 (Fig. 2) for the transferrin receptor. Also, the
fusion protein at 2 ,ug/ml (30 nM) did not inhibit protein
synthesis in either mouse Swiss 3T3 or mouse L929 cells,
reflecting the species specificity of the antibody (Table 1).
Comparison of cytotoxic activities of recombinant immuno-
toxin and chemical conjugate. The activity of anti-TFR(Fv)-
PE40 was assayed on a variety of human cell lines and
compared with that of anti-TFR-LysPE40, the chemical
conjugate composed of the native antibody and PE40 (3). As
shown in Table 1, anti-TFR(Fv)-PE40 inhibited protein
synthesis in all the human cell lines studied, with ID50s
ranging between 0.10 and 92 pM. The chemical conjugate
anti-TFR-LysPE40 was also toxic to these cells. However,
ID50s were up to 750-fold lower than that of the recombinant
single-chain immunotoxin. Both molecules were inactive on
mouse cells, demonstrating their specificity for human trans-
ferrin receptor (Table 1).
Binding of anti-TFR(Fv)-PE40 to the transferrin receptor.
To compare the binding activity of anti-TFR(Fv)-PE40 with
that of the native antibody, competition binding analyses
were performed with HUT102 and A431 cells (Fig. 4). In
these studies, the abilities of various chimeric toxins to
compete for the binding of 1251-HB21 (anti-TFR) to A431
cells was determined. Anti-TFR(Fv)-PE40 was shown to
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FIG. 4. Competition binding analysis of anti-TFR antibody,
HB21, versus anti-TFR(Fv)-PE40. Competition of anti-TFR(Fv)-
PE40 (0), HB21-LysPE40 (-), and native HB21 (0) with 12511
labeled tracer HB21 on HUT102 (A) and A431 (B) cells.
TABLE 2. Activity of DT388-anti-TFR(Fv) on various
human cell lines
Cell Toxin ID50 Ratio of DT-anti-TFR(Fv)
line (pM) to anti-TFR(Fv)-PE40a
A431 88 0.002
KB 82 0.001
MCF7 59 0.002
OVCAR3 34 0.2
HUT102 10 3.7
HT29 16 2.8
L929 15,000
a Ratio of ID50s of DT-anti-TFR(Fv) to those of anti-TFR(Fv)-PE40 on the
same cell line.
compete for binding to the human transferrin receptor very
efficiently; its binding affinity was similar to that of HB21 on
A431 cells and approximately twofold lower on HUT102
cells. In the same experiments, the chemical conjugate
anti-TFR-LysPE40 was tested and found to compete much
less well than native HB21. The binding affinity of anti-TFR-
LysPE40 appears to be about 10-fold lower than that of the
native anti-TFR antibody (Fig. 4).
Cytotoxicity and specificity of DT388-anti-TFR(Fv). DT388-
anti-TFR(Fv) was also prepared, tested, and found to be
cytotoxic to several human cell lines, with ID50s ranging
between 10 and 100 pM (Table 2). Its cytotoxic activity was
also blocked by excess antibody, demonstrating the speci-
ficity of DT388-anti-TFR(Fv) for the transferrin receptor
(data not shown). Furthermore, DT388-anti-TFR(Fv) was
inactive on mouse L929 cells, demonstrating its specificity
for human cells (Table 2). When compared with anti-
TFR(Fv)-PE40, the DT immunotoxin was 400- to 800-fold
less active on A431, KB, and MCF7 cells but 2- to 3-fold
more active on HUT102 and HT29 cells.
DISCUSSION
We have constructed two new single-chain immunotoxins
directed at the human transferrin receptor. One of these is
anti-TFR(Fv)-PE40, which consists of the variable regions of
HB21, a monoclonal antibody to the human transferrin
receptor, joined to PE40, a truncated form of PE devoid of
its binding domain. This fusion protein was expressed in E.
coli and purified to near homogeneity. Anti-TFR(Fv)-PE40
was found to be very cytotoxic to cells bearing human
transferrin receptors. The cytotoxicity was specific, as
shown by competition with excess native antibody. To
demonstrate that it should be possible to make single-chain
immunotoxins that have the same antigen-binding domain
but a different toxin and to compare their activities on
different cell types, we constructed a second single-chain
immunotoxin, DT388-anti-TFR(Fv), containing a truncated
form of DT lacking DT binding activity. This fusion protein
also was found to be cytotoxic to cells expressing the human
transferrin receptor. Unexpectedly, large differences in the
activities of the two single-chain immunotoxins were ob-
served. On some cell lines (A431, KB, and MCF7), anti-
TFR(Fv)-PE40 was at least 100-fold more active than
DT388-anti-TFR(Fv). On two cell lines (HUT102 and HT29),
DT388-anti-TFR(Fv) was about threefold more active. How-
ever, in no case was DT388-anti-TFR(Fv) much more active
than the PE-containing immunotoxin, whereas the reverse
was observed. The basis of these differences in activities
remains to be explored. The mechanism by which immuno-
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toxins kill cells is complex and involves binding to the
receptor, internalization via coated pits into endocytic ves-
icles, and proteolytic processing of the toxin to a form which
can be translocated into the cytosol. It seems unlikely to us
that the difference in the activities is related to binding or the
rate of internalization; instead, the difference probably arises
during the proteolytic processing or translocation steps.
Recently, we have shown that PE is processed by a
cellular protease to produce an N-terminal 28-kDa and a
C-terminal 37-kDa fragment. Only the 37-kDa fragment is
translocated to the cytosol (18). The proteolytic clip oc-
curs at or near Arg-279 in domain I of PE. Production of
the 37-kDa fragment appears to be essential for tox-
icity, since mutant PE molecules PEgly276, PEgly279, and
PEhis274'276'279 that do not produce this fragment are unable
to kill target cells (18). The amino acid sequence at the
carboxyl end of PE is REDLK, and changing it to REDL or
KEDLK does not affect the cytotoxic activity of the toxin
(8). Mutant PE molecules ending with KDEL or RDEL were
fully active, whereas LDER at the carboxyl end resulted in
an inactive molecule, even though the mutant PE molecule
ending with LDER was processed normally, generating the
28- and 37-kDa fragments (18). This observation suggests
that the sequence at the carboxyl end of PE acts as a
recognition sequence to assist translocation of the toxin from
an endocytic compartment to the cytosol (8). Thus, at least
two specific recognition events occur within the cells, one
within domain II that leads to processing and one at the
carboxyl end of domain III. Olsnes and colleagues, using a
system in which whole cells are exposed to a low-pH
environment, have presented strong evidence that a frag-
ment of DT closely resembling the entire A chain is the final
processed form that reaches the cytosol (15). DT contains a
trypsin-sensitive region with three closely spaced arginines
at positions 190, 192, and 193. Cleavage of the toxin to
produce A and B fragments appears to occur in a stochastic
manner after either of these arginine residues (16). The site
of cleavage appears to be one of the factors affecting
translocation, since only A fragments lacking both Arg-192
and Arg-193 were found to be translocation competent (16).
DT does not contain a terminal sequence resembling
REDLK, indicating that it probably has a mechanism of
cellular entry different from that of PE. From the present
study, it appears that despite identical ADP ribosylation
activities, both PE and DT are probably processed or
translocated or both by different mechanisms, resulting in
the differential sensitivity of the cells towards these toxins.
Competition studies showed the binding affinity of anti-
TFR(Fv)-PE40 to be very similar to that of the native
bivalent antibody on A431 cells and HUT102 cells. Since
anti-TFR(Fv)-PE40 is monovalent, this was a somewhat
surprising result. Previously, we had found that anti-
Tac(Fv)-PE40 bound threefold less well than anti-Tac to the
human interleukin 2 receptor-bearing cells, HUT102. On
comparing the cytotoxic activity of anti-TFR(Fv)-PE40 with
that of a chemical conjugate, anti-TFR-Lys(PE40), the
recombinant protein was found to be much more active on
all the human tumor cells investigated. This difference was in
part explained by the diminished binding of the chemical
conjugate to the transferrin receptor, probably as a result of
treatment of the antibody with the modifying 2-iminothiolane
during the preparation of the immunotoxin (3). However,
other steps in immunotoxin action must be differentially
affected as well.
One objective of creating chimeric toxins is their potential
usefulness as antitumor agents. Our previous study shows
that anti-TFR-LysPE40 has a very potent in vivo antitumor
activity against A431 epidermoid carcinomas. Because anti-
TFR(Fv)-PE40 is very cytotoxic to A431 and KB cells in
culture (Table 1), we plan to test anti-TFR(Fv)-PE40 in
animals with these tumors to determine the in vivo antitumor
activity of this single-chain immunotoxin.
In summary, we have shown in the present study as well
as in our earlier report (20) that the single-chain immunotox-
ins made by the fusion of antigen-binding and toxin domains
can retain the binding affinity of the native antibody and are
generally more active than the chemical conjugates. Also,
active single-chain immunotoxins can be made with different
toxin moieties, thus placing antigen-binding portions either
at the amino terminus or the carboxyl terminus as required.
With this information in hand, it should be possible to make
active single-chain immunotoxins from the wide variety of
toxins (plant, bacterial, and animal) that are now being made
by chemical coupling methods (10, 19, 24).
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